Project information | Interferon beta-1b, interferon beta-1a and glatiramer acetate for the treatment of single demyelinating event with clinically isolated syndrome [ID109] | Guidance

Interferon beta-1b, interferon beta-1a and glatiramer acetate for the treatment of single demyelinating event with clinically isolated syndrome (to be included in a review of TA32 - subject to review proposal consultation)

Following on from information provided to NICE by the company in April 2010, the appraisal of Interferon beta-1b, interferon beta-1a and glatiramer acetate for the treatment of single demyelinating event with clinically isolated syndrome [ID109] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.

Status:: Discontinued
Technology type:: Medicine
Decision:: Prioritised
Process:: TA
ID number:: 109
Referral date:: 01 July 2009
Topic area: Central nervous system

Provisional Schedule

Closing date for invited submissions / evidence submission::: TBC
1st appraisal committee meeting::: TBC

Project Team

Communications manager:: TBC
Executive Lead:: TBC
Project manager:: TBC
Technical Lead:: TBC

Email enquiries

If you have any queries please email scheduling@nice.org.uk

Timeline

Key events during the development of the guidance:

Date	Update
23 January 2023	Discontinued. Following on from information provided to NICE by the company in April 2010, the appraisal of Interferon beta-1b, interferon beta-1a and glatiramer acetate for the treatment of single demyelinating event with clinically isolated syndrome [ID109] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
1 April 2010	This technology appraisal was formally referred to the Institute as part of the 21^st wave work programme. The remit was as follows: To appraise the clinical and cost effectiveness of interferon beta-1b, interferon beta-1a and glatiramer acetate within their licensed indications for the treatment of single demyelinating event with clinically isolated syndrome (to be included in a review of TA32). TA32 is currently regarded as ‘static’ guidance and the Institute is of the opinion that this is still appropriate. As a result, this appraisal will not commence at this time due to the remit specifically indicating that it should be included in a review of TA32. As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.

Date

Update

23 January 2023

Discontinued. Following on from information provided to NICE by the company in April 2010, the appraisal of Interferon beta-1b, interferon beta-1a and glatiramer acetate for the treatment of single demyelinating event with clinically isolated syndrome [ID109] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.

1 April 2010

This technology appraisal was formally referred to the Institute as part of the 21^st wave work programme. The remit was as follows:

To appraise the clinical and cost effectiveness of interferon beta-1b, interferon beta-1a and glatiramer acetate within their licensed indications for the treatment of single demyelinating event with clinically isolated syndrome (to be included in a review of TA32).

TA32 is currently regarded as ‘static’ guidance and the Institute is of the opinion that this is still appropriate. As a result, this appraisal will not commence at this time due to the remit specifically indicating that it should be included in a review of TA32.

As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.

For further information on our processes and methods, please see our CHTE processes and methods manual